Antiviral resistance in cytomegalovirus: An emerging problem in organ transplant recipients

Seminars in Respiratory Infections

Volumn 17, Issue 4, 2002, Pages 265-273

  Limaye, Ajit P ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; BRONCHOSCOPY; BRONCHUS BIOPSY; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EXPOSURE; DRUG RESISTANCE; ELECTROLYTE DISTURBANCE; GENE MUTATION; GENOTYPE; GRAFT REJECTION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY GRAFT; LABORATORY DIAGNOSIS; LABORATORY TEST; LUNG TRANSPLANTATION; MALE; MORBIDITY; NEPHROTOXICITY; NEUTROPENIA; PATHOGENESIS; PATHOGENICITY; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SERODIAGNOSIS; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION;

EID: 0036900551     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2002.36447     Document Type: Review

References (39)

1. Erice A, Chou S, Biron KK, et al: Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 320:289-293, 1989
2. Smith IL, Flores-Aguilar M, Taskituna I, et al: Cytomegalovirus resistance is associated with clinical failure in AIDS patients receiving ganciclovir treatment for refinitis [abstract H30]. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC, American Society for Microbiology, 1996
3. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group: Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J Infect Dis 176:508, 1997
4. Wolf DG, Smith IL, Lee DJ, et al: Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 95:257-263, 1995
5. Chou S: Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1: 105-114, 1999
6. Drew WL, Paya CV, Emery V: Cytomegalovirus (CMV) resistance to antivirals. Am J Transpl 1:307-312, 2001
7. Erice A: Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 12:286-297, 1999
8. Chou S, Waldemer RH, Senters AE, et al: Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185:162-169, 2002
9. Crumpacker CS (ed): Drug resistance in cytomegalovirus: Current knowledge and implications for patient management. Proceedings of Roundtable Meeting, Boston, Nov. 18, 1995. J Acquir Immune Defic Syndr Hum Retrovirol 12:S1-S22, 1996 (suppl 1)
10. Chou S, Guentzel S, Michels KR, et al: Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 172: 239-242, 1995
11. Smith IL, Cherrington JM, Jiles RE, et al: High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 176:69-77, 1997
12. Emery VC, Cope AV, Bowen EF, et al: The dynamics of human cytomegalovirus replication in vivo. J Exp Med 190:177-82, 1999
13. Emery VC. Griffiths PD: Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 97:8039-8044, 2000
14. Sia IG, Wilson JA, Groettum CM, et al: Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 181:717-720, 2000
15. Kruger RM, Shannon WD, Arens MQ, et al: The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68:1272-1279, 1999
16. Limaye AP, Raghu G, Koelle DM, et al: High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 185:20-27, 2002
17. Limaye AP, Corey L, Koelle DM, et al: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649, 2000
18. Li W, Anwar F, Jesurrun J. et al: Cytomegalovirus UL97 and glycoprotein B (gB) sequences in tissues from immunocompromised patients with ganciclovir-resistant virus infection. Scand J Infect Dis 31:549-553, 1993
19. Eckle T, Prix L, Jahn G, et al: Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286-3289, 2000
20. Baldanti F, Simoncini L, Sarasini A, et al: Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 66:324-329, 1998
21. Manso JV, Lambert JLR, Ona M, et al: Ganciclovir resistance in a heart transplant recipient infected by cytomegalovirus. Letter to the editor. Int J Cardiol 71:97-98, 1999
22. Aitken C, Barrett-Muir W, Raftery M, et al: The clinical significance of ganciclovir resistance in a renal transplant patient. Letter to the editor. Nephrol Dial Transplant 14:1050-1051. 1999
23. Bienvenu B, Thervet E, Bedrossian J, et al: Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 69:182-184, 2000
24. Ketteler M, Preuschof L, Mertz A, et al: Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient. Clin Nephrol 54:418-424, 2000
25. Mendez JC, Sia IG, Tau KR, et al: Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 67:755-757, 1999
26. Turgeon N, Fishman JA, Doran M, et al: Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: Effect of oral ganciclovir. Transpl Infect Dis 2:2-10, 2000
27. Fishman JA, Doran MT, Volpicelli SA, et al: Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 69:389-394, 2000
28. Rosen HR, Benner KG, Flora KD, et al: Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 63:476-478, 1997
29. Alain, S, Honderlick, P, Grenet D, et al: Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 63:1533-1536, 1997
30. Basgoz N: A 42-year-old lung transplant patient with ganciclovir-resistant cytomegalovirus (CMV) infection. Transpl Infect Dis 1:218-225, 1999
31. Lurain NS, Ammons HC, Kapell KS, et al: Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62:497-502, 1996
32. Razonable RR, Rivero A, Rodriguez A, et al: Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184:1461-1464, 2001
33. Isada CM, Yen-Lieberman B, Kohn D, et al: Emergence of clinically significant ganciclovir (GCV). Resistant strains of CMV in solid organ transplant recipients [abstract 258]. Transplantation 69:S181, 2000
34. Jordan A, Bhorade SM, Lurain NS, et al: Emergence of ganciclovir resistant cytomegalovirus in lung transplant recipients [abstract 79]. Transplantation 1:155, 2001 (suppl 1)
35. Gilbert C, Handfield J, Toma E, et al: Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12:125-129, 1998
36. Nichols WG, Corey L, Gooley T, et al: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 185:273-282, 2002
37. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group: The Cytomegalovirus Retreatment Trial. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 114:23-33, 1996
38. Mylonakis E, Kallas WM, Fishman JA: Combination antiviral therapy for ganciclovir resistant cytomegalovirus infection in solid organ transplant recipients. Clin Infect Dis 34:1337-1341, 2002
39. Limaye A: Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 35:867, 2002